8-K Announcements
6Material company update
Dec 5, 2025·SEC
Material company update
Oct 15, 2025·SEC
Material company update
Oct 9, 2025·SEC
Carisma Therapeutics, Inc.(CARM)Earnings, Financials & Key Ratios
CARM•NASDAQ
Price updated Jun 17, 2026
AboutCarisma Therapeutics, Inc., a biopharmaceutical company, develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response, and technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics, Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics, Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia, Pennsylvania.Show more
- Revenue$20M+31.6%
- EBITDA-$59M+31.5%
- Net Income-$60M+30.4%
- EPS (Diluted)-1.46+43.6%
- Gross Margin-203.96%+48.6%
- EBITDA Margin-299.64%+48.0%
- Operating Margin-316.72%+46.7%
- Net Margin-308.05%+47.1%
CARM Key Insights
Carisma Therapeutics, Inc. (CARM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 23.7% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CARM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CARM Price & Volume
Carisma Therapeutics, Inc. (CARM) stock price & volume — 10-year historical chart
Loading chart...
CARM Growth Metrics
Carisma Therapeutics, Inc. (CARM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years24.23%
5 Years-
3 Years-9.57%
TTM159.68%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM112.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM112.82%
Return on Capital
10 Years-51.33%
5 Years-69.24%
3 Years-104.57%
Last Year-141.24%
CARM Peer Comparison
Carisma Therapeutics, Inc. (CARM) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MGTX | 964.06M | 10.41 | -7.33 | 144.57% | -151.12% | -368.19% | ||
 FATE | 228.46M | 1.96 | -1.70 | -51.24% | -20.57% | -58.89% | 0.38 | |
 SANA | 846.01M | 3.04 | -3.17 | -161.87% | 0.49 | |||
 BEAM | 3.34B | 32.48 | -40.10 | 120.01% | -49.17% | -5.89% | 0.24 | |
 NTLA | 1.71B | 15.20 | -3.99 | 16.92% | -5.97% | -57.27% | 0.14 | |
 CRSP | 5.12B | 53.09 | -8.21 | -89.97% | -138.57% | -30.88% | 0.21 | |
 KYMR | 7.34B | 89.90 | -24.36 | -16.72% | -6.12% | -25.02% | 0.05 | |
 ALNY | 37.72B | 282.72 | 121.34 | 65.19% | 13.46% | 98.29% | 1.62 |
Compare CARM vs Peers
Carisma Therapeutics, Inc. (CARM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CARM Income Statement
Carisma Therapeutics, Inc. (CARM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 29.98M | 425K | 0 | 0 | 11.24M | 26.54M | 9.83M | 14.92M | 19.63M | 52.63M |
Revenue Growth % | 2928.38% | -98.58% | -100% | - | - | 136.24% | -62.95% | 51.71% | 31.59% | 159.68% |
Cost of Goods Sold | 0 | 0 | 208K | 219K | 0 | 85K | 0 | 74.13M | 59.67M | 1.02M |
COGS % of Revenue | - | - | - | - | - | 0.32% | - | 496.85% | 303.96% | - |
Gross Profit | 29.98M▲ 0% | 425K▼ 98.6% | -208K▼ 148.9% | -219K▼ 5.3% | 11.24M▲ 5230.6% | 26.46M▲ 135.5% | 9.83M▼ 62.8% | -59.21M▼ 702.1% | -40.04M▲ 32.4% | 51.61M▲ 0% |
Gross Margin % | 100% | 100% | - | - | 100% | 99.68% | 100% | -396.85% | -203.96% | 98.05% |
Gross Profit Growth % | 2928.38% | -98.58% | -148.94% | -5.29% | 5230.59% | 135.48% | -62.83% | -702.05% | 32.37% | - |
Operating Expenses | 23.64M | 20.13M | 25.49M | 36.65M | 28.38M | 54.62M | 66M | 29.52M | 22.14M | 40.76M |
OpEx % of Revenue | 78.84% | 4735.29% | - | - | 252.56% | 205.77% | 671.1% | 197.9% | 112.76% | - |
Selling, General & Admin | 11.44M | 7.9M | 11.62M | 12.21M | 5.09M | 29.39M | 9.38M | 29.52M | 20.14M | 16.38M |
SG&A % of Revenue | 38.14% | 1858.82% | - | - | 45.27% | 110.73% | 95.36% | 197.9% | 102.58% | - |
Research & Development | 12.2M | 12.22M | 13.87M | 24.44M | 23.29M | 25.23M | 56.62M | 74.13M | 59.67M | 27.36M |
R&D % of Revenue | 40.7% | 2876.47% | - | - | 207.3% | 95.04% | 575.74% | 496.85% | 303.96% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -74.13M | -57.67M | -1.36M |
Operating Income | 6.17M▲ 0% | -19.98M▼ 424.1% | -25.7M▼ 28.6% | -36.87M▼ 43.5% | -28.38M▲ 23.0% | -28.16M▲ 0.8% | -56.16M▼ 99.4% | -88.73M▼ 58.0% | -62.18M▲ 29.9% | 10.85M▲ 0% |
Operating Margin % | 20.57% | -4702.35% | - | - | -252.56% | -106.09% | -571.1% | -594.75% | -316.72% | 20.61% |
Operating Income Growth % | 117.52% | -424.12% | -28.6% | -43.47% | 23.03% | 0.76% | -99.43% | -57.99% | 29.92% | - |
EBITDA | 6.34M | -19.7M | -25.49M | -36.65M | -28.26M | -28.08M | -54.27M | -85.89M | -58.83M | 13.44M |
EBITDA Margin % | 21.16% | -4635.29% | - | - | -251.48% | -105.77% | -551.85% | -575.74% | -299.64% | 25.53% |
EBITDA Growth % | 118.21% | -410.53% | -29.4% | -43.78% | 22.91% | 0.64% | -93.29% | -58.27% | 31.51% | 121.67% |
D&A (Non-Cash Add-back) | 178K | 285K | 208K | 219K | 122K | 85K | 1.89M | 2.84M | 3.35M | 1.69M |
EBIT | 2.14M | -29.03M | -33.69M | -107.5M | -28.38M | -8.61M | -58.08M | -88.73M | -60.18M | 11.97M |
Net Interest Income | 0 | 0 | 0 | 0 | 29K | 10K | -3.15M | 1.94M | 1.7M | 758K |
Interest Income | 0 | 0 | 0 | 0 | 29K | 10K | 0 | 1.94M | 1.7M | 758K |
Interest Expense | 247K | 0 | 0 | 0 | 0 | 0 | 3.15M | 0 | 0 | 0 |
Other Income/Expense | -4.27M | -9.04M | -7.99M | -70.63M | 29K | 19.55M | -5.06M | 1.85M | 1.7M | -2.81M |
Pretax Income | 1.9M▲ 0% | -29.03M▼ 1631.1% | -33.69M▼ 16.1% | -107.5M▼ 219.1% | -28.35M▲ 73.6% | -8.61M▲ 69.6% | -61.23M▼ 611.2% | -86.88M▼ 41.9% | -60.48M▲ 30.4% | 8.04M▲ 0% |
Pretax Margin % | 6.32% | -6830.35% | - | - | -252.31% | -32.43% | -622.6% | -582.34% | -308.05% | 15.28% |
Income Tax | 5K | 0 | 46.86K | 0 | 0 | -8.27M | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0.26% | 0% | -0.14% | 0% | 0% | 96.1% | 0% | 0% | 0% | 0% |
Net Income | 1.89M▲ 0% | -29.03M▼ 1635.1% | -33.69M▼ 16.1% | -107.5M▼ 219.1% | -28.35M▲ 73.6% | -336K▲ 98.8% | -61.23M▼ 18122.0% | -86.88M▼ 41.9% | -60.48M▲ 30.4% | 8.04M▲ 0% |
Net Margin % | 6.31% | -6830.35% | - | - | -252.31% | -1.27% | -622.6% | -582.34% | -308.05% | 15.28% |
Net Income Growth % | 105.65% | -1635.11% | -16.07% | -219.06% | 73.63% | 98.81% | -18122.02% | -41.9% | 30.39% | 112.61% |
Net Income (Continuing) | 1.89M | -29.03M | -33.69M | -107.5M | -28.35M | -336K | -61.23M | -86.88M | -60.48M | 8.04M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 14.39M | 0 | 0 | 0 |
EPS (Diluted) | 1.74▲ 0% | -22.24▼ 1378.2% | -10.91▲ 50.9% | -23.64▼ 116.7% | -3.81▲ 83.9% | -0.04▲ 99.0% | -1.52▼ 4030.4% | -2.59▼ 70.4% | -1.46▲ 43.6% | 0.19▲ 0% |
EPS Growth % | 104.94% | -1378.16% | 50.94% | -116.68% | 83.88% | 99.03% | -4030.43% | -70.39% | 43.63% | 112.82% |
EPS (Basic) | 1.79 | -22.24 | -10.91 | -23.64 | -3.81 | -0.04 | -1.52 | -2.59 | -1.46 | - |
Diluted Shares Outstanding | 1.09M | 1.3M | 3.09M | 4.55M | 5.91M | 9.12M | 40.26M | 33.52M | 41.46M | 41.94M |
Basic Shares Outstanding | 1.05M | 1.3M | 3.09M | 4.55M | 5.91M | 9.12M | 40.26M | 33.52M | 41.46M | 41.79M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CARM Balance Sheet
Carisma Therapeutics, Inc. (CARM) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 25.93M | 14.98M | 51.76M | 54.45M | 62.87M | 205.6M | 54.59M | 80.47M | 23.82M | 5.87M |
Cash & Short-Term Investments | 25.34M | 14.68M | 50.42M | 48.12M | 55.39M | 162.64M | 52M | 77.61M | 18.83M | 2.78M |
Cash Only | 25.34M | 14.68M | 50.42M | 48.12M | 55.39M | 162.64M | 24.19M | 77.61M | 17.91M | 2.78M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 27.8M | 0 | 925K | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 24.49M | 0 | 0 | 2.86M | 1.64M |
Days Sales Outstanding | - | - | - | - | - | 336.8 | - | - | 53.25 | 10.9 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 585K | 301K | 1.33M | 6.33M | 7.48M | 18.48M | 2.6M | 2.87M | 1.79M | 1.46M |
Total Non-Current Assets | 78.17M | 60.12M | 59.8M | 59.92M | 125.59M | 106.99M | 17.56M | 9.08M | 6.63M | 684K |
Property, Plant & Equipment | 796K | 522K | 321K | 238K | 123K | 43K | 13.45M | 8.94M | 6.42M | 684K |
Fixed Asset Turnover | 37.66x | 0.81x | - | - | 91.35x | 617.30x | 0.73x | 1.67x | 3.06x | 21.43x |
Goodwill | 16.86M | 13.06M | 13.06M | 13.06M | 13.06M | 13.06M | 0 | 0 | 0 | 0 |
Intangible Assets | 60.5M | 46.4M | 46.4M | 46.4M | 46.4M | 14.7M | 0 | 0 | 0 | 0 |
Long-Term Investments | 10K | 10K | 20K | 20K | 20K | 20K | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 10K | 120K | 20K | 196K | 349K | 7.32M | 4.11M | 146K | 208K | 0 |
Total Assets | 104.1M▲ 0% | 75.1M▼ 27.9% | 111.56M▲ 48.6% | 114.36M▲ 2.5% | 188.45M▲ 64.8% | 312.6M▲ 65.9% | 72.15M▼ 76.9% | 89.55M▲ 24.1% | 30.46M▼ 66.0% | 6.55M▲ 0% |
Asset Turnover | 0.29x | 0.01x | - | - | 0.06x | 0.08x | 0.14x | 0.17x | 0.64x | 3.63x |
Asset Growth % | 182.68% | -27.86% | 48.56% | 2.51% | 64.78% | 65.87% | -76.92% | 24.12% | -65.99% | -320.34% |
Total Current Liabilities | 3.98M | 4.72M | 6.11M | 8.52M | 18.05M | 11.57M | 19.67M | 15.91M | 16.05M | 6.81M |
Accounts Payable | 1.67M | 907K | 1.37M | 1.9M | 3.1M | 2.85M | 1.73M | 3.93M | 2.08M | 5.57M |
Days Payables Outstanding | - | - | 2.4K | 3.17K | - | 12.25K | - | 19.37 | 12.73 | 1.39K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 425K | 0 | 0 | 0 | 1.5M | 0 | 2.46M | 1.41M | 0 | 0 |
Other Current Liabilities | 1.54M | 3.08M | 4.75M | 4.98M | 11.55M | 5.75M | 3.33M | 4.07M | 4.79M | 1.09M |
Current Ratio | 6.51x | 3.17x | 8.47x | 6.39x | 3.48x | 17.77x | 2.78x | 5.06x | 1.48x | 0.86x |
Quick Ratio | 6.51x | 3.17x | 8.47x | 6.39x | 3.48x | 17.77x | 2.78x | 5.06x | 1.48x | 0.86x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -1.38K |
Total Non-Current Liabilities | 61.44M | 52.34M | 61.24M | 132.55M | 179.63M | 129.32M | 195.15M | 47.11M | 42.31M | 609K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 33.72M | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 1.85M | 1.19M | 744K | 2.69M |
Deferred Tax Liabilities | 16.34M | 12.53M | 12.53M | 12.53M | 78.16M | 75.82M | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 45.1M | 39.81M | 48.71M | 120.02M | 99.97M | 52M | 114.59M | 926K | 41.57M | 0 |
Total Liabilities | 65.42M | 57.06M | 67.35M | 141.06M | 197.68M | 140.89M | 214.82M | 63.02M | 58.37M | 7.42M |
Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 40.16M | 3.12M | 2.48M | 762K |
Net Debt | -25.34M | -14.68M | -50.42M | -48.12M | -55.39M | -162.64M | 15.97M | -74.48M | -15.43M | -2.02M |
Debt / Equity | - | - | - | - | - | - | - | 0.12x | - | -0.88x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.06x |
Net Debt / EBITDA | -3.99x | - | - | - | - | - | - | - | - | -0.15x |
Interest Coverage | 8.68x | - | - | - | - | - | -18.47x | - | - | - |
Total Equity | 38.68M▲ 0% | 18.03M▼ 53.4% | 44.21M▲ 145.1% | -26.7M▼ 160.4% | -9.23M▲ 65.4% | 171.71M▲ 1961.0% | -142.67M▼ 183.1% | 26.53M▲ 118.6% | -27.91M▼ 205.2% | -867K▲ 0% |
Equity Growth % | 104.16% | -53.37% | 145.13% | -160.4% | 65.44% | 1960.95% | -183.09% | 118.6% | -205.19% | -13428.65% |
Book Value per Share | 35.58 | 13.82 | 14.31 | -5.87 | -1.56 | 18.84 | -3.54 | 0.79 | -0.67 | -0.02 |
Total Shareholders' Equity | 38.68M | 18.03M | 44.21M | -26.7M | -9.23M | 171.71M | -157.06M | 26.53M | -27.91M | -867K |
Common Stock | 25K | 35K | 77K | 107K | 140K | 199K | 2K | 40K | 41K | 41K |
Retained Earnings | -123.31M | -152.33M | -186.02M | -293.52M | -315.92M | -316.26M | -158.22M | -245.1M | -305.58M | -279.9M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -71K | -331K | -539K | -758K | 0 | 0 | -41K | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 14.39M | 0 | 0 | 0 |
CARM Cash Flow Statement
Carisma Therapeutics, Inc. (CARM) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 2.62M | -17.77M | -22.83M | -37.52M | -27.01M | -37.33M | -7.57M | -81.18M | -59.92M | -22.41M |
Operating CF Margin % | 8.75% | -4180% | - | - | -240.41% | -140.63% | -76.94% | -544.12% | -305.2% | - |
Operating CF Growth % | 107.59% | -777.54% | -28.51% | -64.36% | 28.01% | -38.19% | 79.73% | -972.92% | 26.19% | 281.25% |
Net Income | 1.89M | -29.03M | -33.69M | -107.5M | -28.35M | -40.78M | -61.23M | -86.88M | -60.48M | 8.04M |
Depreciation & Amortization | 178K | 285K | 208K | 219K | 448K | 682K | 6.09M | 2.84M | 3.35M | 1.33M |
Stock-Based Compensation | 4.01M | 1.38M | 0 | 0 | 163K | 479K | 0 | 2.32M | 3.65M | 2.21M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 4.12M | 11.7M | 10.03M | 72.86M | 1.18M | 834K | 2.37M | 5.99M | 5.51M | 5.29M |
Working Capital Changes | -2.47M | 611K | 578K | -3.1M | -453K | 1.46M | 45.2M | -5.44M | -11.95M | -39.29M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 23.67M | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -742K | -760K | 460K | 535K | 1.28M | -974K | -473K | 2.19M | -1.85M | 3.47M |
Cash from Investing | 461K | 98K | -2K | -136K | -440K | -1.87M | -32.56M | 72.41M | -123K | 687K |
Capital Expenditures | 0 | 0 | -2K | -136K | -440K | -1.87M | -4.66M | -1.13M | -123K | 0 |
CapEx % of Revenue | - | - | - | - | 3.92% | 7.05% | 47.39% | 7.59% | 0.63% | 0% |
Acquisitions | 461K | 98K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 461K | 98K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 687K |
Cash from Financing | -13.82M | 7M | 58.58M | 35.36M | 72.26M | 15.96M | 35.77M | 62.18M | 344K | -2.38M |
Debt Issued (Net) | -14.12M | 0 | 0 | 0 | 0 | 0 | -865K | -1.3M | -1.43M | -515K |
Equity Issued (Net) | 304K | 7M | 58.58M | 35.36M | 72.24M | 16.33M | 35.11M | 30.83M | 2.39M | -18K |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 0 | 0 | 19K | -366K | 1.53M | 32.65M | -619K | -1.84M |
Net Change in Cash | -10.74M▲ 0% | -10.66M▲ 0.7% | 35.74M▲ 435.2% | -2.3M▼ 106.4% | 44.81M▲ 2047.2% | -23.24M▼ 151.9% | -138.44M▼ 495.8% | 53.41M▲ 138.6% | -59.7M▼ 211.8% | -24.1M▲ 0% |
Free Cash Flow | 2.62M▲ 0% | -17.77M▼ 777.5% | -22.83M▼ 28.5% | -37.66M▼ 64.9% | -27.45M▲ 27.1% | -39.2M▼ 42.8% | -12.23M▲ 68.8% | -82.31M▼ 573.2% | -60.04M▲ 27.1% | -22.41M▲ 0% |
FCF Margin % | 8.75% | -4180% | - | - | -244.32% | -147.68% | -124.32% | -551.71% | -305.83% | -42.59% |
FCF Growth % | 107.53% | -777.54% | -28.52% | -64.94% | 27.1% | -42.79% | 68.81% | -573.23% | 27.06% | 67.2% |
FCF per Share | 2.41 | -13.61 | -7.39 | -8.28 | -4.64 | -4.30 | -0.30 | -2.46 | -1.45 | -0.53 |
FCF Conversion (FCF/Net Income) | 1.39x | 0.61x | 0.68x | 0.35x | 0.95x | 111.10x | 0.12x | 0.93x | 0.99x | -2.79x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63K |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CARM Key Ratios
Carisma Therapeutics, Inc. (CARM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 6.56% | -102.38% | -108.27% | -1228.08% | - | -0.41% | -421.67% | -327.45% | - | -28.86% |
Return on Invested Capital (ROIC) | 91.6% | -179.62% | - | - | - | -232.76% | - | - | - | -24.18% |
Gross Margin | 100% | 100% | - | - | 100% | 99.68% | 100% | -396.85% | -203.96% | 98.05% |
Net Margin | 6.31% | -6830.35% | - | - | -252.31% | -1.27% | -622.6% | -582.34% | -308.05% | 15.28% |
Debt / Equity | - | - | - | - | - | - | - | 0.12x | - | -0.88x |
Interest Coverage | 8.68x | - | - | - | - | - | -18.47x | - | - | - |
FCF Conversion | 1.39x | 0.61x | 0.68x | 0.35x | 0.95x | 111.10x | 0.12x | 0.93x | 0.99x | -2.79x |
Revenue Growth | 2928.38% | -98.58% | -100% | - | - | 136.24% | -62.95% | 51.71% | 31.59% | 159.68% |
Related:CARM Dividend History·CARM Revenue History·CARM Price History·CARM P/E History·CARM Financial Ratios·CARM Institutional Holders
CARM SEC Filings & Documents
Carisma Therapeutics, Inc. (CARM) SEC filings — annual & quarterly reports (10-K, 10-Q)
CARM Frequently Asked Questions
Carisma Therapeutics, Inc. (CARM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Carisma Therapeutics, Inc. (CARM) reported $52.6M in revenue for fiscal year 2024.
Carisma Therapeutics, Inc. (CARM) grew revenue by 31.6% over the past year. This is strong growth.
Yes, Carisma Therapeutics, Inc. (CARM) is profitable, generating $8.0M in net income for fiscal year 2024 (-308.1% net margin).
Dividend & Returns
Carisma Therapeutics, Inc. (CARM) had negative free cash flow of $22.4M in fiscal year 2024, likely due to heavy capital investments.